Examkin

Question

Difficulty: HardInfectious Diseases

A 65-year-old man is evaluated in the hospital for management of infective endocarditis. He was admitted three days ago after presenting with a one-week history of fevers, severe fatigue, and night sweats. His medical history is significant for hypertension and stage 3a chronic kidney disease with a baseline serum creatinine of 1.6 mg/dL.

Upon admission, multiple sets of blood cultures were obtained, and the patient was started on empiric intravenous vancomycin and piperacillin-tazobactam. Transthoracic echocardiography performed yesterday demonstrated a 1.2-cm mobile vegetation on the anterior leaflet of the native mitral valve.

Today, the microbiology laboratory finalizes the blood culture results, reporting that all four bottles are growing *Enterococcus faecalis*. The isolate is susceptible to ampicillin, vancomycin, gentamicin, and linezolid.

Based on current clinical guidelines, which of the following is the most appropriate definitive antimicrobial regimen for this patient?

  1. Intravenous ampicillin and intravenous ceftriaxoneAnswer
  2. B
    Intravenous ampicillin and intravenous gentamicin
  3. C
    Intravenous vancomycin and intravenous ceftriaxone
  4. D
    Intravenous ampicillin monotherapy
  5. E
    Intravenous piperacillin-tazobactam monotherapy

Answer

The most appropriate definitive regimen is the combination of intravenous ampicillin and intravenous ceftriaxone.
The correct answer is the combination of intravenous ampicillin and intravenous ceftriaxone. *Enterococcus faecalis* infective endocarditis requires a bactericidal regimen, which is achieved through dual antibiotic therapy. While ampicillin monotherapy is bacteriostatic against enterococci, the addition of a second agent provides synergistic bactericidal activity. Large clinical trials have demonstrated that the combination of ampicillin and ceftriaxone is equally effective as the historical standard (ampicillin plus an aminoglycoside) for treating *E. faecalis* endocarditis, but is associated with a significantly lower risk of nephrotoxicity. This remarkable synergy occurs because ceftriaxone saturates specific penicillin-binding proteins (PBPs) that ampicillin does not effectively target, leading to complete cell wall breakdown despite the organism's intrinsic resistance to cephalosporin monotherapy. Given this patient's pre-existing chronic kidney disease, avoiding nephrotoxic agents like gentamicin is critical, making ampicillin and ceftriaxone the definitive regimen of choice.

Step-by-Step Solution

1
Analyze the microbiological data and diagnosis.
The patient has native valve infective endocarditis caused by ampicillin-susceptible *Enterococcus faecalis*.
Establishing the precise pathogen and its susceptibility profile is required to transition from empiric broad-spectrum therapy to targeted therapy.
2
Determine the pharmacological requirements for treating enterococcal endocarditis.
A synergistic, bactericidal regimen is necessary because beta-lactam monotherapy (like ampicillin alone) is only bacteriostatic against enterococci.
Endocarditis is an endovascular infection with high bacterial density that requires bactericidal action for complete pathogen eradication and clinical cure.
3
Evaluate the patient's comorbidities to select the safest and most effective synergistic regimen.
The patient has stage 3a chronic kidney disease. The combination of ampicillin and ceftriaxone provides the necessary bactericidal synergy without the nephrotoxicity associated with aminoglycosides.
Antibiotic stewardship involves selecting the most effective therapy while actively minimizing adverse effects based on patient-specific physiological factors.

Key Concept

Definitive management of *Enterococcus faecalis* infective endocarditis requires synergistic bactericidal therapy; the combination of ampicillin and ceftriaxone is a first-line regimen that is strongly preferred over ampicillin and gentamicin in patients with baseline renal impairment.
Rate this question

Topics

Infectious Diseases

More questions from this topic